Non-melanoma skin cancer would account for more than 24 million new cases of cancer worldwide, according to the World Cancer Research Fund International (WCRF). In 2017, the National Cancer Institute (NIH) reported that over 1.5 million new cases of cancer were discovered in the country. Products for cancer supportive care are designed to aid patients in overcoming the side effects of treatment. As a result, the growth of this industry is directly related to rising cancer rates.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-cancer-supportive-care-products-market
Data Bridge Market Research analyses that The Cancer Supportive Care Products Market was valued at USD 20,124.54 million in 2021 and is further estimated to reach USD 24,519.80 million by 2029, and is expected to grow at a CAGR of 2.5% during the forecast period of 2022 to 2029. The development of new cancer treatments, such as chemotherapy, radiation therapy, and targeted therapies, has improved patient outcomes but also introduced side effects. Supportive care products play a crucial role in managing these side effects, such as nausea, pain, fatigue, anemia, and oral mucositis, thereby enhancing patients' quality of life and treatment adherence.
Advancements in cancer treatments is expected to drive the market's growth rate
With advancements in cancer treatments such as chemotherapy, radiation therapy, and targeted therapies, survival rates have improved. However, these treatments often lead to side effects that can negatively impact patients' well-being and treatment adherence. Supportive care products play a crucial role in managing these side effects, including nausea, pain, fatigue, and psychological distress. Alleviating these symptoms, supportive care products help patients tolerate and complete their treatment regimens more effectively, ultimately improving treatment outcomes.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014-2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drug Class (Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor), Indication (Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Acacia Pharma Group Plc (Poland), Teva Pharmaceuticals Industries Ltd (Israel), Fagron Group (Poland), KYOWA HAKKO BIO CO., LTD. (Japan), APR (Switzerland), and F. Hoffmann-La Roche Ltd (Switzerland)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The cancer supportive care products market is segmented on the basis of drug class, indication and distribution channel.
- On the basis of drug class, global cancer supportive care products market is segmented into granulocyte colony stimulating factor (GCSFs), erythropoietin stimulating agents (ESA’s), opioid analgesics, monoclonal antibodies, nonsteroidal anti-inflammatory drugs (NSAIDs), bisphosphonates, anti-emetics, antihistamines and others. Granulocyte colony stimulating factor (GCSFs), segment is dominating the market with a CAGR of 5.8% in the forecast year of 2022 to 2029 due to it stimulates the bone marrow and generates stem cells as well as granulocytes to discharge it in bloodstream. Moreover, granulocyte colony stimulating factor (GCSFS) is primarily used to treat and cure the neutropenia caused owing to cancer chemotherapy treatment.
In 2022, Granulocyte colony stimulating factor (GCSFs), segment is dominating the drug class of the global cancer product market
Granulocyte colony stimulating factor (GCSFs), segment is dominating the market owing to the bone marrow and generates stem cells as well as granulocytes to discharge it in bloodstream. Moreover, granulocyte colony stimulating factor (GCSFS) is primarily used to treat and cure the neutropenia caused owing to cancer chemotherapy treatment with a CAGR of 5.8% in the forecast year of 2022 to 2029
- On the basis of indication, global cancer supportive care products market is segmented into lung cancer, breast cancer, prostate cancer, liver cancer, bladder cancer, leukemia, melanoma, ovarian cancer and other cancers. The lung cancer segment is dominating the market with a CAGR of 7.2% in the forecast year of 2022 to 2029 due to growing smoking habits among populace in developed as well as developing country.
In 2022, the lung cancer segment is dominating the indication segment of the global cancer supportive care products market
The lung cancer segment is dominating the market owing to the growing smoking habits among populace in developed as well as developing country with a CAGR of 7.2% in the forecast year of 2022 to 2029.
- On the basis of distribution channel, global cancer supportive care products market is segmented into hospital pharmacies, retail pharmacies and compounding pharmacies. Hospital pharmacies segment is dominating the market with a CAGR of 5.3% in the forecast year of 2022 to 2029 due to increasing adoption of prescription based medicines in hospitals also acts as driver for the cancer supportive care products market growth.
Major Players
Data Bridge Market Research recognizes the following companies as the major cancer supportive care products market players in cancer supportive care products market are Acacia Pharma Group Plc (Poland), Teva Pharmaceuticals Industries Ltd (Israel), Fagron Group (Poland), KYOWA HAKKO BIO CO., LTD. (Japan), APR (Switzerland), and F. Hoffmann-La Roche Ltd (Switzerland)
Market Development
- In 2021, several companies have focused on developing advanced formulations and delivery systems for managing oral microsites, a common side effect of cancer treatment. These innovations aim to provide effective relief and promote faster healing of oral ulcers.
- In January 2020, Novartis AG declared the acquisition with the Medicines Company. This acquisition has provided novel opportunity to the company to escalate its geographical presence across the world as well as, it has helped in upgrading the product portfolio of the company.
- In 2020, Merck made a significant impact at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 by presenting over 30 abstracts. These abstracts likely covered diverse topics related to oncology research, clinical trials, and advancements in cancer treatment, showcasing Merck's commitment to scientific innovation in the field.
- In 2020, Bristol Myers Squibb reported that Idhifa, which the FDA has approved for relapsed or refractory AML with an IDH2 mutation, which earlier failed to demonstrate efficacy in improving survival in the same patient population when given in conjunction with the best supportive care in a late-stage study.
- In 2019, Johnson & Johnson Services, Inc. declared the acquisition with TARIS Biomedical LLC. Whereas TARIS Biomedical LLC is the biotechnology company and helped in advancing the novel drug delivery technology for the therapy of bladder diseases as well as for cancer treatment.
Regional Analysis
Geographically, the countries covered in the cancer supportive care products market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
As per Data Bridge Market Research analysis:
North America is the dominant region in cancer supportive care products market during the forecast period 2022 - 2029
North America holds a dominant position in the cancer supportive care products market, driven by the rise in biosimilars adoption. The availability of biosimilars at lower prices than biologics has led to cost savings in cancer treatment. Additionally, the region's focus on research and development of pharmaceutical drugs supports the growth of the market. These factors, along with the high average price of biologics, contribute to North America's continued growth in the cancer supportive care products market during the forecast period.
Asia-Pacific is estimated to be the fastest growing region in cancer supportive care products market the forecast period 2022 - 2029
The Asia-Pacific region is expected to experience substantial growth in the biosimilars market, which in turn will drive the growth of the cancer supportive care products market. The region's rising prevalence of cancer and the associated side effects of cancer treatment create a demand for supportive care products. As more patients seek effective solutions to manage symptoms and improve their quality of life, the market for cancer supportive care products is anticipated to flourish in the Asia-Pacific region in the coming years.
For more detailed information about the cancer supportive care products market report, click here – https://www.databridgemarketresearch.com/reports/global-cancer-supportive-care-products-market
